| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 100,192 | 99,840 |
| Net increase (decrease) in cash and cash equivalents | 492 | 33,971 |
| Cash and cash equivalents at beginning of period | 152,596 | - |
| Cash and cash equivalents at end of period | 153,088 | - |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)